The medical foods for inborn errors of metabolism market size has grown rapidly in recent years. It will grow from $2.72 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The expansion observed during the historical period can be ascribed to several factors, including global health initiatives, heightened acknowledgment of nutritional therapies, the adoption of precision medicine approaches, a rising incidence of metabolic disorders, and the emergence of personalized digital nutrition platforms.
The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $4.83 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be linked to various factors, including the integration of telehealth, an increasing demand for clean label products, the extension of newborn screening programs, the adoption of patient-centric care models, and the development of plant-based and sustainable formulations. Key trends expected in the forecast period encompass technological advancements in genetic testing, progress in food processing technologies, innovations in ingredient technology, and the continuous evolution of food formulation technologies.
The projected increase in genetic (inherited) disorders is anticipated to be a key driver for the growth of the medical foods for inborn errors of metabolism market in the future. Genetic disorders, stemming from deviations in the typical DNA sequence, are expected to contribute to the demand for specialized nutrition provided by medical foods. These products play a crucial role in addressing the unique metabolic needs of individuals with metabolic abnormalities, preventing nutritional deficits, and promoting overall growth and well-being. For instance, data from May 2021 indicated that in the United States alone, a gene variant diagnosed 1 in 200,000 individuals with syndrome A each year, while globally, 15,000 patients with syndrome B have been identified. This surge in genetic disorders is a significant factor propelling the growth of the medical foods for inborn errors of metabolism market.
The growing aging population is poised to drive the expansion of the medical food for inborn errors of metabolism market in the coming years. The aging population trend, characterized by an increasing proportion of elderly individuals globally, presents challenges associated with nutritional requirements and metabolic issues specific to certain disorders in older individuals. Notably, projections from the World Health Organization in October 2022 estimate that by 2030, 1 in every 6 individuals worldwide will be 60 years old or older. During this period, the population aged 60 and over is expected to increase from 1 billion in 2020 to 1.4 billion. Looking ahead, the global population of individuals aged 60 and older is set to double, reaching 2.1 billion by 2050. As a result, the rising aging population emerges as a significant factor propelling the growth of the medical food for inborn errors of metabolism market.
Product innovation stands out as a prominent trend gaining traction in the medical food for inborn errors of metabolism market. Key players in this market are strategically focusing on the development of innovative products to enhance their market position. An example of this trend is evident in the actions of SFI Health, a Switzerland-based natural healthcare company, which introduced EQUAZEN PRO in December 2021. This specially formulated medical food caters to the dietary treatment of conditions with specific nutritional requirements for omega fatty acid levels. EQUAZEN PRO is designed to promote healthy fatty acid metabolism and restore optimal omega-heavy acid levels. Scientifically proven to improve brain health in children and adolescents with ADHD and associated neurodiverse diseases, EQUAZEN PRO contains sustainably sourced fish oils and evening primrose oil. The capsule shell composition ensures gastro resistance, delaying the transfer of fish oil from the stomach to the intestine and preventing potential fishy flavor or reflux.
Major companies in the medical food for inborn errors of metabolism market are also directing their efforts towards developing innovative metabolic products, such as solid-dose protein substitutes, to address dietary management needs and gain a competitive edge. A notable example is Galen Medical Nutrition, an Ireland-based company, which, in October 2022, introduced TYR EASY Tablets into the UK market. These unique solid-dose protein substitutes for tyrosinemia are provided in tablet form and cater to patients over the age of 8, offering more options for protein substitutes tailored to their daily requirements.
In June 2021, Vitaflo International, a UK-based clinical nutrition company, made a strategic acquisition by purchasing Dr. Schär products, Mevalia, and ComidaMed, along with its manufacturing facility in Germany. This acquisition, conducted for an undisclosed amount, enhances Vitaflo's product portfolio for Inborn Errors of Metabolism (IEM) and expands its geographic footprint. The acquired brands, Mevalia and ComidaMed, contribute to the dietary management of IEM and cow’s milk protein allergy. Mevalia, in particular, specializes in protein supplements for phenylketonuria (PKU), while ComidaMed offers hypoallergenic powdered mixtures for IEM. This strategic move bolsters Vitaflo's position in the medical food for inborn errors of metabolism market.
Major companies operating in the medical foods for inborn errors of metabolism market report are BASF SE, Abbott Laboratories Inc., Danone SA, Bristol-Myers Squibb Co, Meiji Holdings Co Ltd., Nestlé Health Science S.A., Ajinomoto Corporation, Mount Sinai Health System, BioMarin Pharmaceutical Inc., Gerber Products Company, Metagenics Inc., Vitaflo International, SHS International Limited, Merck $ Co Inc., Galen Medical Group, Applied Nutrition Corp., Primus Pharmaceuticals Inc., Reckitt Benckiser Group Plc, Ener-G Foods Inc., Pristine Organics Pvt. Ltd., Cymbiotika LLC, BC Children's Hospital, NutriScience Innovations LLC, Solace Nutrition LLC.
North America was the dominant region in the medical foods for inborn errors of metabolism market in 2023. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical foods for inborn errors of metabolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
These medical foods cater to a range of disorders, including phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, methylmalonic acidemia, organic acidurias, propionic acidemia, isovaleric acidemia, disorders of leucine metabolism, glutaric acidemia type I, renal disease, and others. Tailored for various age groups such as infants, weaning, adolescents, and adults, these products are available in diverse forms such as powders, liquids, gels, and more. Distribution channels include retail pharmacies, hospital pharmacies, drug stores, online pharmacies, and other relevant outlets.
The medical foods for inborn errors of metabolism market research report is one of a series of new reports that provides medical foods for inborn errors of metabolism market statistics, including medical foods for inborn errors of metabolism industry global market size, regional shares, competitors with a medical foods for inborn errors of metabolism market share, detailed medical foods for inborn errors of metabolism market segments, medical foods for inborn errors of metabolism market trends and opportunities, and any further data you may need to thrive in the medical foods for inborn errors of metabolism industry. This medical foods for inborn errors of metabolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The medical food for inborn errors of the metabolism market consists of sales of galactose-free formulas, modified starches and carbohydrate supplements, and Vitamin pyridoxine (B6) supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The medical foods for inborn errors of metabolism market size is expected to see rapid growth in the next few years. It will grow to $4.83 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period can be linked to various factors, including the integration of telehealth, an increasing demand for clean label products, the extension of newborn screening programs, the adoption of patient-centric care models, and the development of plant-based and sustainable formulations. Key trends expected in the forecast period encompass technological advancements in genetic testing, progress in food processing technologies, innovations in ingredient technology, and the continuous evolution of food formulation technologies.
The projected increase in genetic (inherited) disorders is anticipated to be a key driver for the growth of the medical foods for inborn errors of metabolism market in the future. Genetic disorders, stemming from deviations in the typical DNA sequence, are expected to contribute to the demand for specialized nutrition provided by medical foods. These products play a crucial role in addressing the unique metabolic needs of individuals with metabolic abnormalities, preventing nutritional deficits, and promoting overall growth and well-being. For instance, data from May 2021 indicated that in the United States alone, a gene variant diagnosed 1 in 200,000 individuals with syndrome A each year, while globally, 15,000 patients with syndrome B have been identified. This surge in genetic disorders is a significant factor propelling the growth of the medical foods for inborn errors of metabolism market.
The growing aging population is poised to drive the expansion of the medical food for inborn errors of metabolism market in the coming years. The aging population trend, characterized by an increasing proportion of elderly individuals globally, presents challenges associated with nutritional requirements and metabolic issues specific to certain disorders in older individuals. Notably, projections from the World Health Organization in October 2022 estimate that by 2030, 1 in every 6 individuals worldwide will be 60 years old or older. During this period, the population aged 60 and over is expected to increase from 1 billion in 2020 to 1.4 billion. Looking ahead, the global population of individuals aged 60 and older is set to double, reaching 2.1 billion by 2050. As a result, the rising aging population emerges as a significant factor propelling the growth of the medical food for inborn errors of metabolism market.
Product innovation stands out as a prominent trend gaining traction in the medical food for inborn errors of metabolism market. Key players in this market are strategically focusing on the development of innovative products to enhance their market position. An example of this trend is evident in the actions of SFI Health, a Switzerland-based natural healthcare company, which introduced EQUAZEN PRO in December 2021. This specially formulated medical food caters to the dietary treatment of conditions with specific nutritional requirements for omega fatty acid levels. EQUAZEN PRO is designed to promote healthy fatty acid metabolism and restore optimal omega-heavy acid levels. Scientifically proven to improve brain health in children and adolescents with ADHD and associated neurodiverse diseases, EQUAZEN PRO contains sustainably sourced fish oils and evening primrose oil. The capsule shell composition ensures gastro resistance, delaying the transfer of fish oil from the stomach to the intestine and preventing potential fishy flavor or reflux.
Major companies in the medical food for inborn errors of metabolism market are also directing their efforts towards developing innovative metabolic products, such as solid-dose protein substitutes, to address dietary management needs and gain a competitive edge. A notable example is Galen Medical Nutrition, an Ireland-based company, which, in October 2022, introduced TYR EASY Tablets into the UK market. These unique solid-dose protein substitutes for tyrosinemia are provided in tablet form and cater to patients over the age of 8, offering more options for protein substitutes tailored to their daily requirements.
In June 2021, Vitaflo International, a UK-based clinical nutrition company, made a strategic acquisition by purchasing Dr. Schär products, Mevalia, and ComidaMed, along with its manufacturing facility in Germany. This acquisition, conducted for an undisclosed amount, enhances Vitaflo's product portfolio for Inborn Errors of Metabolism (IEM) and expands its geographic footprint. The acquired brands, Mevalia and ComidaMed, contribute to the dietary management of IEM and cow’s milk protein allergy. Mevalia, in particular, specializes in protein supplements for phenylketonuria (PKU), while ComidaMed offers hypoallergenic powdered mixtures for IEM. This strategic move bolsters Vitaflo's position in the medical food for inborn errors of metabolism market.
Major companies operating in the medical foods for inborn errors of metabolism market report are BASF SE, Abbott Laboratories Inc., Danone SA, Bristol-Myers Squibb Co, Meiji Holdings Co Ltd., Nestlé Health Science S.A., Ajinomoto Corporation, Mount Sinai Health System, BioMarin Pharmaceutical Inc., Gerber Products Company, Metagenics Inc., Vitaflo International, SHS International Limited, Merck $ Co Inc., Galen Medical Group, Applied Nutrition Corp., Primus Pharmaceuticals Inc., Reckitt Benckiser Group Plc, Ener-G Foods Inc., Pristine Organics Pvt. Ltd., Cymbiotika LLC, BC Children's Hospital, NutriScience Innovations LLC, Solace Nutrition LLC.
North America was the dominant region in the medical foods for inborn errors of metabolism market in 2023. The regions covered in the medical foods for inborn errors of metabolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical foods for inborn errors of metabolism market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
These medical foods cater to a range of disorders, including phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, methylmalonic acidemia, organic acidurias, propionic acidemia, isovaleric acidemia, disorders of leucine metabolism, glutaric acidemia type I, renal disease, and others. Tailored for various age groups such as infants, weaning, adolescents, and adults, these products are available in diverse forms such as powders, liquids, gels, and more. Distribution channels include retail pharmacies, hospital pharmacies, drug stores, online pharmacies, and other relevant outlets.
The medical foods for inborn errors of metabolism market research report is one of a series of new reports that provides medical foods for inborn errors of metabolism market statistics, including medical foods for inborn errors of metabolism industry global market size, regional shares, competitors with a medical foods for inborn errors of metabolism market share, detailed medical foods for inborn errors of metabolism market segments, medical foods for inborn errors of metabolism market trends and opportunities, and any further data you may need to thrive in the medical foods for inborn errors of metabolism industry. This medical foods for inborn errors of metabolism market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The medical food for inborn errors of the metabolism market consists of sales of galactose-free formulas, modified starches and carbohydrate supplements, and Vitamin pyridoxine (B6) supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Medical Foods For Inborn Errors of Metabolism Market Characteristics3. Medical Foods For Inborn Errors of Metabolism Market Trends and Strategies32. Global Medical Foods For Inborn Errors of Metabolism Market Competitive Benchmarking33. Global Medical Foods For Inborn Errors of Metabolism Market Competitive Dashboard34. Key Mergers and Acquisitions in the Medical Foods For Inborn Errors of Metabolism Market
4. Medical Foods For Inborn Errors of Metabolism Market - Macro Economic Scenario
5. Global Medical Foods For Inborn Errors of Metabolism Market Size and Growth
6. Medical Foods For Inborn Errors of Metabolism Market Segmentation
7. Medical Foods For Inborn Errors of Metabolism Market Regional and Country Analysis
8. Asia-Pacific Medical Foods For Inborn Errors of Metabolism Market
9. China Medical Foods For Inborn Errors of Metabolism Market
10. India Medical Foods For Inborn Errors of Metabolism Market
11. Japan Medical Foods For Inborn Errors of Metabolism Market
12. Australia Medical Foods For Inborn Errors of Metabolism Market
13. Indonesia Medical Foods For Inborn Errors of Metabolism Market
14. South Korea Medical Foods For Inborn Errors of Metabolism Market
15. Western Europe Medical Foods For Inborn Errors of Metabolism Market
16. UK Medical Foods For Inborn Errors of Metabolism Market
17. Germany Medical Foods For Inborn Errors of Metabolism Market
18. France Medical Foods For Inborn Errors of Metabolism Market
19. Italy Medical Foods For Inborn Errors of Metabolism Market
20. Spain Medical Foods For Inborn Errors of Metabolism Market
21. Eastern Europe Medical Foods For Inborn Errors of Metabolism Market
22. Russia Medical Foods For Inborn Errors of Metabolism Market
23. North America Medical Foods For Inborn Errors of Metabolism Market
24. USA Medical Foods For Inborn Errors of Metabolism Market
25. Canada Medical Foods For Inborn Errors of Metabolism Market
26. South America Medical Foods For Inborn Errors of Metabolism Market
27. Brazil Medical Foods For Inborn Errors of Metabolism Market
28. Middle East Medical Foods For Inborn Errors of Metabolism Market
29. Africa Medical Foods For Inborn Errors of Metabolism Market
30. Medical Foods For Inborn Errors of Metabolism Market Competitive Landscape and Company Profiles
31. Medical Foods For Inborn Errors of Metabolism Market Other Major and Innovative Companies
35. Medical Foods For Inborn Errors of Metabolism Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Medical Foods For Inborn Errors Of Metabolism Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on medical foods for inborn errors of metabolism market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for medical foods for inborn errors of metabolism? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Product: Amino Acid; Glytactin with GMP Amino Acid-Modified Infant Formula with Iron; Low-Calcium/Vitamin D-Free Infant Formula with Iron; Low Protein Food; Other Products
2) By Diseases: Phenylketonuria (PKU); Maple Syrup Urine Disease (MSUD); Homocystinuria; Methylmalonic Acidemia; Organic Acidurias; Propionic Acidemia; Isovaleric Acidemia; Disorders of Leucine Metabolism; Glutaric Acidemia Type I Renal Disease; Other Diseases
3) By Age Group: Infants; Weaning; Adolescent; Adults
4) By Forms: Powder; Liquids; Gels; Other Forms
5) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Drugs Stores; Online Pharmacies; Other Distribution Channels
Key Companies Mentioned: BASF SE; Abbott Laboratories Inc; Danone SA; Bristol-Myers Squibb Co; Meiji Holdings Co Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BASF SE
- Abbott Laboratories Inc
- Danone SA
- Bristol-Myers Squibb Co
- Meiji Holdings Co Ltd.
- Nestlé Health Science S.A.
- Ajinomoto Corporation
- Mount Sinai Health System
- BioMarin Pharmaceutical Inc
- Gerber Products Company
- Metagenics Inc.
- Vitaflo International
- SHS International Limited
- Merck $ Co Inc.
- Galen Medical Group
- Applied Nutrition Corp.
- Primus Pharmaceuticals Inc.
- Reckitt Benckiser Group Plc
- Ener-G Foods Inc
- Pristine Organics Pvt. Ltd.
- Cymbiotika LLC
- BC Children's Hospital
- NutriScience Innovations LLC
- Solace Nutrition LLC
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.08 Billion |
| Forecasted Market Value ( USD | $ 4.83 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
